NVAX
bellwetherreport.com: BellwetherReport.com Issues Morning Alert for Novavax Inc.
May 19, 2006 (M2 PRESSWIRE via COMTEX) -- The Bellwether Report Takes Notice of Novavax Inc. (Nasdaq:NVAX) Novavax has a thing for women and their health. The company focuses primarily on prescription pharmaceuticals for women. It sells such products as pre-natal vitamins, oral contraceptives, and hormone replacement therapies. The company's topical creams include ESTRASORB and ANDROSORB, which deliver estrogen and testosterone through the skin. Novavax is also developing vaccines for the flu, HIV/AIDS, melanoma, and E-selectin tolerogen (secondary stroke prevention). In addition, the company is developing a vaccine for hepatitis E in collaboration with GlaxoSmithKline.
Shares were up 3% following the announcement that the Company will develop a novel medicine for women.
Novavax, Inc. today announced that it has entered into a definitive agreement with Esprit Pharma to co-develop, supply and commercialize Novavax's(TM) micellar nanoparticle testosterone medicine currently in development to treat female hypoactive sexual desire disorder (HSDD).
Women who suffer from HSDD have low sexual desire. Approximately 25% of women in the United States are estimated to be affected by this condition. Novavax's testosterone medicine, which applied as a lotion, is currently in Phase II
clinical development.
Under terms of the License Agreement, Esprit will receive exclusive rights to market the product in North America. Esprit will make certain minimum payments to Novavax upon the achievement of pre-determined clinical and regulatory
milestones, and royalties on all net sales of the product. The anticipated milestone and royalty payments from.....
